Do analysts rate ACTU or GELS?

Actuate Therapeutics currently has a consensus price target of $10.50, indicating a potential upside of 1,444.12%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Actuate Therapeutics is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ACTU or GELS?

Gelteq has higher revenue and earnings than Actuate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A Gelteq $110K 53.16 -$4.30M N/A N/A

Is ACTU or GELS more profitable?

Gelteq's return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% Gelteq N/A N/A N/A

Do analysts recommend GELS or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, GELS or PLRZ?

Polyrizon has lower revenue, but higher earnings than Gelteq. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 53.16 -$4.30M N/A N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is GELS or PLRZ more profitable?

Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Polyrizon N/A N/A N/A

Does the media prefer GELS or PLRZ?

In the previous week, Gelteq and Gelteq both had 3 articles in the media. Polyrizon's average media sentiment score of 0.60 beat Gelteq's score of 0.21 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Polyrizon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GELS or QNTM?

Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 107.79%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Quantum Biopharma is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, GELS or QNTM?

Gelteq has higher revenue and earnings than Quantum Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 53.16 -$4.30M N/A N/A Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A

Is GELS or QNTM more profitable?

Gelteq's return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Quantum Biopharma N/A -582.23% -184.20%

Does the media refer more to GELS or QNTM?

In the previous week, Quantum Biopharma had 5 more articles in the media than Gelteq. MarketBeat recorded 8 mentions for Quantum Biopharma and 3 mentions for Gelteq. Quantum Biopharma's average media sentiment score of 0.85 beat Gelteq's score of 0.21 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend COCP or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, COCP or GELS?

Gelteq has higher revenue and earnings than Cocrystal Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A Gelteq $110K 53.16 -$4.30M N/A N/A

Is COCP or GELS more profitable?

Gelteq's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -207.47% -123.33% Gelteq N/A N/A N/A

Do analysts recommend AYTU or GELS?

Aytu BioPharma currently has a consensus price target of $14.50, indicating a potential upside of 535.96%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, AYTU or GELS?

Gelteq has lower revenue, but higher earnings than Aytu BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aytu BioPharma $57.57M 0.43 -$13.56M -$1.66 N/A Gelteq $110K 53.16 -$4.30M N/A N/A

Does the media favor AYTU or GELS?

In the previous week, Aytu BioPharma had 10 more articles in the media than Gelteq. MarketBeat recorded 13 mentions for Aytu BioPharma and 3 mentions for Gelteq. Aytu BioPharma's average media sentiment score of 0.33 beat Gelteq's score of 0.21 indicating that Aytu BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aytu BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Gelteq (GELS) Competitors

$0.55 0.00 (-0.73%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$0.54 0.00 (-0.55%)

As of 09/25/2026 07:57 PM Eastern

Compare

GELS vs. ACTU, PLRZ, QNTM, COCP, and AYTU

Should you buy Gelteq stock or one of its competitors? Gelteq's main competitors and comparable companies include Actuate Therapeutics (ACTU), Polyrizon (PLRZ), Quantum Biopharma (QNTM), Cocrystal Pharma (COCP), and Aytu BioPharma (AYTU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Gelteq compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Gelteq has higher revenue and earnings than Actuate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Gelteq	$110K	53.16	-$4.30M	N/A	N/A

Actuate Therapeutics currently has a consensus price target of $10.50, indicating a potential upside of 1,444.12%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Actuate Therapeutics is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gelteq had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.79 beat Gelteq's score of 0.21 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Very Positive
Gelteq	Neutral

Actuate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, suggesting that its share price is 141% less volatile than the broader market.

Gelteq's return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Gelteq	N/A	N/A	N/A

Summary

Actuate Therapeutics and Gelteq tied by winning 5 of the 10 factors compared between the two stocks.

How does Gelteq compare to Polyrizon?

Gelteq (NASDAQ:GELS) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Polyrizon	N/A	N/A	N/A

Gelteq has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.39, meaning that its stock price is 239% less volatile than the broader market.

Polyrizon has lower revenue, but higher earnings than Gelteq.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	53.16	-$4.30M	N/A	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gelteq and Gelteq both had 3 articles in the media. Polyrizon's average media sentiment score of 0.60 beat Gelteq's score of 0.21 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polyrizon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gelteq and Polyrizon tied by winning 2 of the 4 factors compared between the two stocks.

How does Gelteq compare to Quantum Biopharma?

Gelteq (NASDAQ:GELS) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Gelteq has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Gelteq's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Quantum Biopharma	N/A	-582.23%	-184.20%

Gelteq has higher revenue and earnings than Quantum Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	53.16	-$4.30M	N/A	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 107.79%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Quantum Biopharma is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.2% of Quantum Biopharma shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Quantum Biopharma had 5 more articles in the media than Gelteq. MarketBeat recorded 8 mentions for Quantum Biopharma and 3 mentions for Gelteq. Quantum Biopharma's average media sentiment score of 0.85 beat Gelteq's score of 0.21 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Quantum Biopharma beats Gelteq on 8 of the 12 factors compared between the two stocks.

How does Gelteq compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Gelteq has higher revenue and earnings than Cocrystal Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Gelteq	$110K	53.16	-$4.30M	N/A	N/A

Cocrystal Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.7% of Cocrystal Pharma shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Gelteq's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Gelteq	N/A	N/A	N/A

In the previous week, Gelteq had 2 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.82 beat Gelteq's score of 0.21 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cocrystal Pharma	Very Positive
Gelteq	Neutral

Summary

Gelteq beats Cocrystal Pharma on 5 of the 9 factors compared between the two stocks.

How does Gelteq compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Aytu BioPharma had 10 more articles in the media than Gelteq. MarketBeat recorded 13 mentions for Aytu BioPharma and 3 mentions for Gelteq. Aytu BioPharma's average media sentiment score of 0.33 beat Gelteq's score of 0.21 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gelteq	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aytu BioPharma has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, indicating that its stock price is 141% less volatile than the broader market.

Gelteq has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Gelteq's return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-24.76%	-56.54%	-13.14%
Gelteq	N/A	N/A	N/A

Aytu BioPharma currently has a consensus price target of $14.50, indicating a potential upside of 535.96%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gelteq has lower revenue, but higher earnings than Aytu BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$57.57M	0.43	-$13.56M	-$1.66	N/A
Gelteq	$110K	53.16	-$4.30M	N/A	N/A

33.5% of Aytu BioPharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aytu BioPharma beats Gelteq on 9 of the 14 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.89M	$12.54B	$7.27B	$13.10B
Dividend Yield	N/A	2.63%	2.52%	13.51%
P/E Ratio	N/A	789.85	274.41	25.75
Price / Sales	53.16	748.37	618.37	86.14
Price / Cash	N/A	91.64	79.23	52.93
Price / Book	0.51	10.51	10.43	6.30
Net Income	-$4.30M	$2.81B	$3.49B	$359.77M
7 Day Performance	-2.83%	-0.96%	-1.25%	-0.23%
1 Month Performance	-5.83%	-2.99%	-4.67%	-3.88%
1 Year Performance	-61.00%	1.06%	15.06%	5.35%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	0.6954 of 5 stars	$0.55 -0.7%	N/A	-59.6%	$5.89M	$110K	N/A	8	Analyst Forecast Short Interest Increase
ACTU Actuate Therapeutics	3.6255 of 5 stars	$0.98 -1.4%	$10.50 +970.1%	-89.8%	$23.56M	N/A	N/A	12	Positive News Gap Up
PLRZ Polyrizon	0.9216 of 5 stars	$10.99 -0.4%	N/A	+69.3%	$23.51M	N/A	N/A	1
QNTM Quantum Biopharma	2.9399 of 5 stars	$3.66 -1.6%	$8.00 +118.6%	-77.4%	$23.42M	N/A	N/A	7	News Coverage
COCP Cocrystal Pharma	1.1352 of 5 stars	$1.18 +3.9%	N/A	-6.4%	$23.31M	N/A	N/A	10	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. ACTU, PLRZ, QNTM, COCP, and AYTU

How does Gelteq compare to Actuate Therapeutics?

Summary

How does Gelteq compare to Polyrizon?

Summary

How does Gelteq compare to Quantum Biopharma?

Summary

How does Gelteq compare to Cocrystal Pharma?

Summary

How does Gelteq compare to Aytu BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. ACTU, PLRZ, QNTM, COCP, and AYTU

How does Gelteq compare to Actuate Therapeutics?

Which has better valuation & earnings, ACTU or GELS?

Do analysts rate ACTU or GELS?

Does the media refer more to ACTU or GELS?

Which has more volatility & risk, ACTU or GELS?

Is ACTU or GELS more profitable?

Summary

How does Gelteq compare to Polyrizon?

Is GELS or PLRZ more profitable?

Which has more volatility and risk, GELS or PLRZ?

Which has preferable valuation & earnings, GELS or PLRZ?

Do analysts recommend GELS or PLRZ?

Does the media prefer GELS or PLRZ?

Summary

How does Gelteq compare to Quantum Biopharma?

Which has more risk and volatility, GELS or QNTM?

Is GELS or QNTM more profitable?

Which has higher valuation and earnings, GELS or QNTM?

Do analysts rate GELS or QNTM?

Do insiders and institutionals hold more shares of GELS or QNTM?

Does the media refer more to GELS or QNTM?

Summary

How does Gelteq compare to Cocrystal Pharma?

Which has preferable earnings and valuation, COCP or GELS?

Which has more volatility & risk, COCP or GELS?

Do analysts recommend COCP or GELS?

Do institutionals and insiders have more ownership in COCP or GELS?

Is COCP or GELS more profitable?

Does the media favor COCP or GELS?

Summary

How does Gelteq compare to Aytu BioPharma?

Does the media favor AYTU or GELS?

Which has more risk & volatility, AYTU or GELS?

Is AYTU or GELS more profitable?

Do analysts recommend AYTU or GELS?

Which has higher valuation & earnings, AYTU or GELS?

Do insiders & institutionals believe in AYTU or GELS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools